1. Home
  2. TRVG vs AKBA Comparison

TRVG vs AKBA Comparison

Compare TRVG & AKBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo trivago N.V.

TRVG

trivago N.V.

BUY

Current Price

$3.98

Market Cap

282.2M

Sector

Technology

ML Signal

BUY

Logo Akebia Therapeutics Inc.

AKBA

Akebia Therapeutics Inc.

HOLD

Current Price

$0.67

Market Cap

248.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TRVG
AKBA
Founded
2005
2007
Country
Germany
United States
Employees
893
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
282.2M
248.3M
IPO Year
2015
2014

Fundamental Metrics

Financial Performance
Metric
TRVG
AKBA
Price
$3.98
$0.67
Analyst Decision
Hold
Buy
Analyst Count
5
6
Target Price
★ $5.95
$3.92
AVG Volume (30 Days)
178.3K
★ 6.5M
Earning Date
11-03-2026
11-09-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 93.94
EPS
★ N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$15.24
N/A
Revenue Next Year
$9.60
N/A
P/E Ratio
$16.98
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.59
$0.69
52 Week High
$6.80
$3.19

Technical Indicators

Market Signals
Indicator
TRVG
AKBA
Relative Strength Index (RSI) 28.79 26.24
Support Level $2.72 N/A
Resistance Level $5.77 $0.98
Average True Range (ATR) 0.27 0.04
MACD -0.10 -0.02
Stochastic Oscillator 3.33 5.64

Price Performance

Historical Comparison
TRVG
AKBA

About TRVG trivago N.V.

trivago NV is a hotel search company focused on reshaping the way travelers search for and compare hotels while enabling hotel advertisers to grow their businesses by providing access to a broad audience of travelers through the company's websites and apps. The platform allows travelers to make informed decisions by personalizing their hotel search and providing access to a deep supply of hotel information and prices. The company operates in three operating segments, namely the Americas, Developed Europe, and the Rest of the World. Its geographic areas are the United States, Germany, the United Kingdom, Canada, Japan, and all other countries.

About AKBA Akebia Therapeutics Inc.

Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor approved in Japan for the treatment of anemia due to chronic kidney disease, and HIF-PH inhibitors in preclinical development.

Share on Social Networks: